Background

- 5% lidocaine-medicated plasters (LMPs) are included in the local Formulary but only for use in post-herpetic neuralgia. Use for other indications is non-Formulary.
- Data from September 2015 – September 2016 showed an “outside hospital” (which has since been clarified as “mainly hospice”), i.e. Marie Curie Glasgow (MCG) annual spend of £18,896 on LMPs (261 packs).

The use of LMPs totalled 14% of MCG drug expenditure with evidence suggesting that there is an overall doubtful benefit to their use.

Research Questions

- How many patients were prescribed LMPs in the IPU in October 2016?
- Why was the LMP prescribed and was it in line with current evidence and recommendations?

Aim

To reduce total spend on a treatment of doubtful benefit.

Methods

- A retrospective analysis of case notes for inpatients admitted in October 2016 was undertaken.
- Patients were identified through PalCare.
- Data was collected from notes using a modified form used previously in NHSGGC acute sector.

Results

- 35% of patients admitted to the IPU (12/34) had been prescribed LMPs:
  - 67% of prescriptions had been initiated prior to admission

0% of prescriptions were for post-herpetic neuralgia
- 50% of LMP prescriptions were in line with current Scottish Palliative Care Guidelines
- 0% had a baseline site specific pain assessment
- 17% had an assessment of their pain 48hrs post admission
- 8% had a localised skin reaction to the LMP
- 33% died with LMPs still in-situ
- 50% of patients were discharged on LMPs with no plan for review

Conclusions

- Baseline site specific pain at initiation and then benefit – pain assessment and patient perception – should be assessed at 48 hours and 1 week.
- A 24hr patch free period should be trialled if the pain resolves; after, if the pain resumes, the LMP should be restarted.
- Application site reactions are common and should be reviewed.
- Review of benefit in the in-patient setting and community post-discharge, discontinuing the LMP if no benefit is had, is warranted.

Update

- A new LMP - with identical bioequivalence and indications of use to that currently used - is now available; at 15% less cost.
- New evidence shows efficacy in localised neuropathic pain and suggests LMPs have a role in multimodal analgesia in those at risk of adverse side effects.

References:

1 Derry S. et al. Topical lidocaine for neuropathic pain in adults. Cochrane Database of Systematic Reviews 2014
2 www.palliativecareguidelines.scot.nhs.uk
3 Medicines Update Primary Care July 2017

For further information please contact: sheonad.laidlaw@mariecurie.org.uk